Pharmaceutical CAS 90779-69-4 Atosiban Peptide Atosiban Acetate Powder Atosiban

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Atosiban
• Product Name: Atosiban
• Name: Atosiban Powder
• Appearance: White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Oxytocin
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 90779-69-4
• Mf: C43h67n11o12s2
• MW: 994.19
• Density: 1.254+-0.06 g/cm3(Predicted)
• Melting Point: >165 C (DEC.)
• Boiling Point: 1469.0+-65.0 C(Predicted)
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500 Kg/Month

Product Description

Pharmaceutical CAS 90779-69-4 Atosiban Peptide Atosiban Acetate Powder Atosiban

 

Product Description

Product Details

Product Name	Atosiban
CAS No.	90779-69-4
MF	C43H67N11O12S2
MW	994.19
Appearance and shape	White powder

Atosiban Acetate is an inhibitor of the hormones oxytocin and vasopressin.   It is used intravenously to halt premature labor.
Atosiban is a synthetic peptide oxytocin antagonist.   It binds to membrane bound oxytocin receptors on the myometrium and prevents oxytocin-stimulated increases in inositol triphosphate production.   This prevents release of stored calcium from the sarcoplasmic reticulum and subsequent opening of voltage gated calcium channels.   This shutdown of cytosolic calcium increase prevents contractions of the uterine muscle, reducing the frequency of contractions and inducing uterine quiescence.

Application & Function

Atosiban was introduced in the UK as an injectable inhibitor of preterm labor, a major cause of infant morbidity and mortality.   This peptidic oxytocin analog is an antagonist of the vasopressin V1a receptor and of the oxytocin receptor which is found in dramatically increased concentration in the uterine myometrium of pregnant women near term.   It competitively inhibited contractions in the pregnant guinea pig uterus induced by oxytocin and vasopressin.   In a multicenter, double-blind, placebo-controlled trial, treatment with atosiban caused pregnancy prolongation for up to 7 days in women with more than 28 weeks of gestation.   In a comparative clinical trial, atosiban showed a comparable tocolytic action (uterine relaxant) to ritodrine but the former was significantly better tolerated, especially with regards to maternal cardiovascular side effects.   In healthy volunteers, plasma levels of atosiban decreased bi-exponentially with an initial and a terminal half-life of 21 min and 1.7h respectively.

Specification